Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
581-600 of 998 trials

Bladder Cancer: Nadofaragene Firadenovec Treatment

We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.

High-risk Non-Muscle-Invasive Bladder Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Fluid Overload in ICU: Furosemide Treatment

We are studying whether a diuretic called furosemide helps critically ill patients with fluid overload recover better than a placebo. The focus is on increasing the number of days alive and out of the hospital after 90 days.

Fluid Overload>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Colorectal Polypectomy: Anticoagulation Study

We are investigating whether continuing blood-thinning medication during polypectomy is safe for patients. The goal is to see if it helps reduce the risk of blood clots during the procedure.

Patients on Anticoagulants for Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyHematology

Primary Hyperoxaluria: DCR-PHXC Injection Study

We are evaluating a new injection for patients with Primary Hyperoxaluria to see how it affects kidney function and overall safety. The study also looks at its impact on kidney stones and quality of life.

Primary Hyperoxaluria>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Triple Negative Breast Cancer: Sacituzumab Govitecan and Pembrolizumab Study

We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.

Triple Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Lung Cancer: Amivantamab and Lazertinib Study

We are exploring a new treatment combination for people with advanced non-small cell lung cancer who have an EGFR mutation and have not responded to earlier therapies. The goal is to see if this combination can improve treatment outcomes and safety.

Advanced Non-Small Cell Lung Cancer (NSCLC)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Head and Neck Cancer: Carboplatin, Paclitaxel, and Cetuximab Study

We are studying a combination of three medications for patients with recurrent or metastatic head and neck squamous cell carcinoma who did not respond to previous treatments. The goal is to see if this combination improves response rates and overall survival.

Head and Neck Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Migraine Prevention in Kids: Rimegepant Study

We are testing a new medication, rimegepant, to see if it helps reduce migraine days in children and adolescents aged 6 to under 18. The study compares its effects to a placebo to understand its potential benefits.

Migraine≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Cardiac Surgery: Fibrinogen Concentrate Study

We are testing a new treatment to manage bleeding in patients undergoing complex cardiac surgery. The goal is to see if it reduces the need for blood transfusions compared to a placebo.

Functional Disturbances After Cardiac SurgeryBleeding in Cardiac Surgery Patients>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Pancreatic Cancer: New Electroporation Treatments

We are studying the effects of three innovative treatments for pancreatic cancer to see if they improve quality of life and survival. This includes assessing pain levels and weight loss in patients.

Unresectable Pancreatic Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

CIDP Treatment: Rituximab Study

We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Locally Recurrent Rectal Cancer: Induction Chemotherapy Study

We are comparing the effects of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone for patients with locally recurrent rectal cancer. This study aims to see which approach leads to better surgical outcomes and survival rates.

Recurrent Rectal CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Botox for Inability to Belch

We are studying whether Botox injections into the upper esophageal sphincter can help people who struggle to belch. This trial compares the effects of Botox with a placebo to assess symptom improvement.

Esophageal Disorders>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyOtolaryngology

HER2-Positive Gastric Cancer: Rilvegostomig Treatment Study

We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.

HER2-positive Gastric Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Urinary Tract Infections: OM-89 Treatment Study

We are investigating whether OM-89 can help reduce antibiotic use in patients with a neurological bladder due to spinal cord injury. This study will compare its effects to a placebo over two years.

Recurrent Urinary Tract InfectionsNeurogenic Bladder1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInfectious DiseasesUrology

GTX-102 for Children with Angelman Syndrome

We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.

Angelman's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Diabetic Foot Ulcers: Comparing Two Treatments

We are studying whether Hypochlorous Acid or Polyhexamethylene biguanide helps heal diabetic foot ulcers more effectively. This trial will also look at healing size, depth, and quality of life for participants.

Diabetic Foot Ulcer3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteDiabetologyInfectious DiseasesInternal Medicine

Primary Aldosteronism: New Imaging Technique Study

We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.

Primary Hyperaldosteronism1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology